Ischemic Heart Disease and Chronic Obstructive Pulmonary Disease Hospitalizations in Japan Before and After the Introduction of a Heated Tobacco Product

Plas, Angela van der; Antunes, Meagan; Romero-Kauss, Alba; Hankins, Matthew J.; Heremans, Annie

doi:10.3389/fpubh.2022.909459

Cited by 7 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cessation is and must remain the primary goal in the ght against smoking. However, for those who would otherwise continue to smoke cigarettes-particularly in Italy, where the rate of smokers was still 26.2% in May 2021 (a total of about 11.3 million smokers) [29]-a harm reduction approach, based on robust scienti c evidence should be considered [30], as scienti cally substantiated products that do not burn tobacco have the potential to replace cigarettes and contribute to the reduction of smoking-related harms [31][32][33][34]. Our ndings among Italian IQOS™ users indicate that the use of alternative TNPs has the potential to reduce the number of cigarette smokers in Italy.…”

Section: Discussionmentioning

confidence: 99%

Use of IQOSTM (a heated tobacco product) in Italy: A cross-sectional survey

Pellegatti

Paparatti

2022

Preprint

View full text Add to dashboard Cite

Background: Limited data are available on the use of heated tobacco products (HTPs) and specifically the use of IQOS™ in Italy. Here, we present the results of a cross-sectional survey on a randomly selected sample of registered of IQOS™ legal age users with the aim of assessing their use behaviors associated with IQOS™ and previous tobacco use history to better understand patterns of IQOS™ use at individual and population levels in Italy. Methods: A quantitative survey on 3002 interviews was conducted from May 20 to May 26, 2020, on a sample of IQOS™ users of both sexes, aged 18-80 years and who had used at least 100 tobacco units (HEETSTM) in their lifetime. Results: The mean age at the time of starting using IQOSTM was 36.3 years. Only 0.8% had started regularly (at least 1 HEETSTM per day) using IQOS™ at 16-<18 years, whereas the majority started at 25-44 years (52.5%). For 64% of respondents, IQOS™ was their exclusive tobacco product, whereas 36% used IQOS™ in combination with another tobacco and/or nicotine product (TNP) (mainly IQOS™ and cigarettes: 25%). Ninety percent of IQOS™ users were cigarette smokers (89.7%) or e-cigarette users (0.3%) at the time when they started using IQOS™. Only 0.6% had never smoked, and 8.3% were former cigarette smokers or e-cigarette users when they started to use IQOS™. Conclusions: The vast majority of respondents were already smokers when they switched to IQOS™, suggesting that the product does not pose a strong risk of attracting nicotine-naïve users. Further, most IQOS™ users in this survey reported they no longer smoke cigarettes. Our findings indicate that the use of alternative TNPs has the potential to reduce the number of cigarette smokers in Italy.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of IQOSTM (a heated tobacco product) in Italy: A cross-sectional survey

Pellegatti

Paparatti

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…62 A recent realworld evidence study analysed hospitalisation numbers associated with COPD using data from the Japanese Medical Data Center (JMDC) over this same time period. 63 Careful evaluation of all available data from the JMDC database revealed a significant reduction in the number of hospitalisations for COPD and a non-significant reduction in hospitalisations for COPD plus lower respiratory tract infections after the 2014 THS introduction (Figure 2).…”

Section: Pre-clinical Findingsmentioning

confidence: 99%

“…the estimated study completion date is June 2027.The increasing trend of COPD hospitalisations turned downward in 2017, shortly after the introduction of HTPs to Japan. COPD: chronic obstructive pulmonary disease; HTP: heated tobacco product; JMDC: Japanese Medical Data Center.Adapted from van der Plas et al63 …”

mentioning

confidence: 99%

Heated Tobacco Products and Chronic Obstructive Pulmonary Disease: A Narrative Review of Peer-Reviewed Publications

Popp¹,

Reese

Scotti

2023

EMJ

View full text Add to dashboard Cite

An estimated 65 million people worldwide have moderate or severe chronic obstructive pulmonary disease (COPD), an umbrella term used to describe a group of progressive lung diseases that obstruct airflow such as emphysema and chronic bronchitis. Smoking contributes to an estimated 90% of COPD cases, as the harmful chemicals produced during tobacco combustion damage the lungs and airways. Although smoking cessation is the only intervention shown to improve COPD prognosis in smokers, many patients who try to quit continue to smoke. The continued use of conventional cigarettes exacerbates COPD symptoms, and globally more than 3 million people die from the disease every year. The last two decades have seen the introduction of combustion-free nicotine delivery alternatives that produce significantly lower levels of the harmful components in cigarette smoke, and researchers have begun to assess the impact of switching from cigarettes to these products. Several studies have examined how patients with COPD use e-cigarettes as assistance for quitting, but few have examined how heated tobacco products (HTP) may reduce risk. This narrative review summarises results from pre-clinical, clinical, and real-world evidence studies showing possible harm reduction benefits for patients with COPD who switch to HTPs rather than continuing to smoke cigarettes. Epidemiological studies, real-world data analyses, and randomised clinical trials must be conducted to determine whether switching from cigarettes to HTPs can improve health outcomes in patients with COPD who would otherwise continue to smoke combustible cigarettes.

show abstract

“…For example, HNB technologies were first introduced to the Japanese market in 2014, allowing for a real-world study of hospitalisations for COPD before and after their use. 33 Analyses of real-word evidence provided the first evidence that HNB technologies could considerably reduce the consumption of conventional cigarettes among active smokers (p<0.01), and may also significantly reduce hospitalisations due to acute exacerbations of COPD. 33 A 5-year follow-up cohort study from Kazakhstan evaluating exacerbations, symptoms, and lung function in people who used IQOS (n=400) compared with cigarette smokers (n=801) has published preliminary data from the 2-year follow-up.…”

Section: Clinical Evidence Basementioning

confidence: 99%

“…33 Analyses of real-word evidence provided the first evidence that HNB technologies could considerably reduce the consumption of conventional cigarettes among active smokers (p<0.01), and may also significantly reduce hospitalisations due to acute exacerbations of COPD. 33 A 5-year follow-up cohort study from Kazakhstan evaluating exacerbations, symptoms, and lung function in people who used IQOS (n=400) compared with cigarette smokers (n=801) has published preliminary data from the 2-year follow-up. 34 Szondy said: "Persons aged between 40 and 59 years who had been smoking for at least 10 years and had switched to using mainly HNB products (>70%) were recruited as subjects, while the control group consisted of persons in the same age groups who smoked conventional cigarettes."…”

Section: Clinical Evidence Basementioning

confidence: 99%

Current Evidence on Tobacco Harm Reduction in Pneumology: Interviews with Two Key Opinion Leaders

Barrell¹

2022

EMJ

View full text Add to dashboard Cite

The negative impact of smoking on the lung is well documented. Cigarette smoke is the cause of 90% of cases of chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. COPD is a progressive and debilitating condition with morbidity and mortality rates similar to myocardial infarction (MI) and stroke. Despite the widely recognised risks, millions of people continue to smoke, in some cases even after receiving a diagnosis of COPD and despite knowing that the habit will accelerate disease progression. While there is no doubt that smoking cessation is the most important health intervention for all cigarette smokers, it can be challenging. Nicotine addiction, social norms and culture, and the length of time it can take smokers to feel the adverse consequences of the habit all contribute to the high cessation failure rate. However, increasing clinical and epidemiological evidence indicates that for those who are unwilling or cannot stop smoking, harm reduction strategies can help reduce exposure to the harmful chemicals and carcinogens released during tobacco combustion. Electronic devices heat processed tobacco without combusting it to deliver an aerosol containing fewer toxic products or harmful and potentially harmful constituents (HPHC) than cigarette smoke. Clinical evidence to support their use is growing. In Japan, for example, a decrease in hospitalisations due to COPD exacerbation after the introduction of such heat-not-burn (HNB), or tobacco heating systems (THS), has been reported. In this article, Wolfgang Popp, Döbling Doctor’s Center, Privatklinik Döbling, Vienna, Austria, and Klara Szondy, Semmelweis University, Budapest, Hungary, discuss the impact of cigarette smoke on the lung, and how to support smoking cessation in those willing and able to quit smoking. They also explain when strategies that reduce the harmful effects of smoking may be useful, and outline the latest evidence supporting the use of HNB systems.

show abstract

Ischemic Heart Disease and Chronic Obstructive Pulmonary Disease Hospitalizations in Japan Before and After the Introduction of a Heated Tobacco Product

Cited by 7 publications

References 8 publications

Use of IQOSTM (a heated tobacco product) in Italy: A cross-sectional survey

Use of IQOSTM (a heated tobacco product) in Italy: A cross-sectional survey

Heated Tobacco Products and Chronic Obstructive Pulmonary Disease: A Narrative Review of Peer-Reviewed Publications

Current Evidence on Tobacco Harm Reduction in Pneumology: Interviews with Two Key Opinion Leaders

Contact Info

Product

Resources

About